TRAW · Onconova Therapeutics, Inc.

This PIPE financing represents a critical capital infusion for Traws Pharma’s near-term clinical development strategy, specifically targeting the advancement of tivoxavir marboxil — its oral small-molecule influenza antiviral — through a UK human challenge trial. The structure is deliberately tiered: $10 million in upfront proceeds provides immediate runway, while the $50 million in contingent warrant proceeds align incentives with key milestones — regulatory greenlight (Series A), clinical data readout (Series B), and governance approval (Series C). Notably, the Series C Warrants constitute the largest tranche (17.95M shares) and include a call feature that allows the Company to cancel unexercised warrants if the stock price sustains a 200% premium over the strike for 30 days, protecting against dilution in a rising market. The financing was executed 'at-the-market' under Nasdaq rules, signaling alignment with current trading levels. Placement agent fees (6.0% of gross proceeds) and the mandatory S-3 registration commitment reflect standard market terms for a biotech early-stage financing, but the tight 30-day filing deadline and escalating liquidated damages (1.0% per month, capped at 5%) underscore investor emphasis on liquidity and transparency. Management explicitly frames the use of proceeds around de-risking the influenza program, with no mention of general corporate purposes or balance sheet strengthening — indicating this is purely a clinical catalyst play. The forward-looking statements in Exhibit 99.1 highlight material execution risks: the FDA clinical hold on tivoxavir marboxil’s IND, the need to satisfy MHRA requirements, and the uncertainty of achieving the warrant-triggering milestones, all of which could materially impact the realization of the full $60 million capital pool.